N
OBIO icon

Nuveen’s Orchestra BioMed OBIO Stock Holding History

Nuveen’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,729
Closed -$179K – 3366
2025
Q1 		$179K Hold
41,729
– – ﹤0.01% 3146
2024
Q4 		$167K Hold
41,729
– – ﹤0.01% 3231
2024
Q3 		$214K Hold
41,729
– – ﹤0.01% 3210
2024
Q2 		$340K Buy
41,729
+19,433
+87% +$113K ﹤0.01% 3117
2024
Q1 		$118K Buy
22,296
+10,290
+86% +$69.7K ﹤0.01% 3240
2023
Q4 		$110K Buy
+12,006
New +$82K ﹤0.01% 3278

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen's OBIO Position: Q2 2025 in Review

Nuveen sold out of Orchestra BioMed (OBIO) in Q2 2025, closing a stake of 41,729 shares — an estimated $179K sold.

Nuveen first reported a position in OBIO in Q4 2023 and held it in 6 quarters. The position peaked at $340K in Q2 2024. 59 funds tracked by Wall St. Rank hold OBIO as of Q2 2025.

  • Nuveen reported no remaining Orchestra BioMed position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 41,729 Orchestra BioMed shares in Q2 2025, an estimated $179K.
  • Nuveen first reported a position in Orchestra BioMed in Q4 2023 and held it in 6 quarters.
  • Nuveen's Orchestra BioMed position peaked at $340K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.